PR Newswire
NASHVILLE, Tenn., Oct. 25, 2016
NASHVILLE, Tenn., Oct. 25, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals
Inc. (NASDAQ: CPIX) announced today that it will release third quarter 2016 financial results after the market closes on
Tuesday, November 1, 2016. A conference call and live Internet webcast will be held on
Tuesday, November 1, 2016, at 4:30 p.m. Eastern Time to discuss the
results.
To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A
rebroadcast of the teleconference will be available for one week and can be accessed by dialing 855-859-2056 (for U.S. callers)
or 404-537-3406 (for international callers). The Conference ID for the rebroadcast is 99386514. The live webcast and
rebroadcast can be accessed via Cumberland's website at http://investor.shareholder.com/cpix/events.cfm.
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on acquisition, development, and
commercialization of high-quality products that improve the quality of care for patients. The Company has a diverse product
portfolio with a focus in the areas of hospital acute care and gastroenterology. Cumberland's
marketed products include Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning,
Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, Kristalose® (lactulose) for Oral Solution, a prescription laxative,
Vaprisol® (conivaptan) Injection, for the treatment of hyponatremia, Omeclamox-Pak® for the
treatment of H. pylori and duodenal ulcer disease, and Ethyol® (amifostine) for Injection, for the treatment of
oncology patients Cumberland is dedicated to also developing innovative products that
address unmet medical needs. The Company's product candidates in clinical development include: Hepatoren®
(ifetroban) Injection for the treatment of hepatorenal syndrome, Boxaban® (ifetroban) Oral Capsule for
patients suffering from aspirin exacerbated respiratory disease, and Vasculan™ (ifetroban) Oral Capsule for
the treatment of systemic sclerosis. For more information on Cumberland Pharmaceuticals Inc., please visit www.cumberlandpharma.com.
Logo - http://photos.prnewswire.com/prnh/20140505/84325
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-to-announce-third-quarter-2016-financial-results-300350503.html
SOURCE Cumberland Pharmaceuticals Inc.
